Researchers’ blood cancer breakthrough

August 10, 2011, University of Southampton

Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed.

Non-Hodgkin’s is the sixth most common cancer in the UK and causes around 4,500 deaths a year in the UK, with a rise in cases reported. The most successful advance in treatment in recent years has been a drug called rituximab, which works by ‘tagging’ the surface of the tumour so they can be sought out and destroyed by the patient’s own immune system.

Unfortunately, an estimated 30% of patients do not respond to treatment. Professors Mark Cragg, Peter Johnson and Martin Glennie and their teams at the University Of Southampton Faculty Of Medicine are investigating reasons behind this.

They found that in some lymphoma patients, after binding to the surface of the cancer cells, rituximab is quickly internalised inside the cell. This means that the drug does not work as it should and immune cells cannot seek out and kill the cancer cells as effectively.

The results of the team’s research, which was co-funded by the charity Leukaemia & Lymphoma Research, the Medical Research Council, Research UK and Tenovus, Cardiff are published online in the medical journal Blood.

Through a series of laboratory tests, the Southampton scientists crucially noticed that rituximab is internalised much faster by the lymphoma cells when a molecule called ‘FcgRIIb’ is also present at high levels. In a small, preliminary analysis, the researchers found that those patients with high amounts of this molecule on their lymphoma were less likely to be treated successfully. They are now moving forward with a much bigger analysis to confirm their findings.

Professor Cragg said: “The discovery that high levels of FcgRllb on lymphoma cells can determine how effective rituximab will be could be very significant. It may be that different, non-internalising antibodies are needed for certain patients. FcgRllb is also a potential target for new drugs to work alongside standard treatments.”

Dr. David Grant, Scientific Director at Leukaemia & Lymphoma Research, said: “Treatment for non-Hodgkin’s lymphoma has made rapid progress but clearly a significant number of patients do not respond to drugs like rituximab. Understanding exactly why they don’t respond is vital so that new drugs can be designed to make sure that every patient survives.”

Dr. Ian Lewis, Associate Director of Research at Tenovus, said “In addition to helping us devise new drugs and therapeutic strategies for the treatment of lymphoma, this discovery could also help us to identify those who will not respond to treatment with rituximab and therefore offer them alternative, more effective treatments at a much earlier stage”.

Explore further: Key cause of bone marrow failure identified

Related Stories

Key cause of bone marrow failure identified

May 3, 2011
(Medical Xpress) -- Researchers funded by Leukaemia & Lymphoma Research and the Medical Research Council (MRC) have identified one of the first steps that can cause bone marrow failure and eventually lead to blood cancers. ...

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.